- Trials with a EudraCT protocol (314)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
314 result(s) found for: Grafting.
Displaying page 1 of 16.
EudraCT Number: 2017-002462-41 | Sponsor Protocol Number: TBRU-dS-RAC-PII | Start Date*: 2018-10-29 |
Sponsor Name:CUTISS AG | ||
Full Title: A Phase II, prospective, intra-patient randomized controlled, multicentre study to evaluate the safety and efficacy of an autologous bio-engineered dermo-epidermal skin substitute (EHSG-KF) for the... | ||
Medical condition: Adults and children with full thickness skin defects | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: NL (Trial now transitioned) IT (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2017-002460-41 | Sponsor Protocol Number: TBRU-dS-BA-PIIb | Start Date*: 2018-10-29 |
Sponsor Name:CUTISS AG | ||
Full Title: A Phase IIb, prospective, intra-patient randomised controlled, multicentre study to evaluate the safety and efficacy of an autologous bio-engineered dermo-epidermal skin substitute (EHSG-KF) for th... | ||
Medical condition: Adults and adolescents with partial deep dermal and full thickness burns | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Trial now transitioned) IT (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2017-002461-21 | Sponsor Protocol Number: TBRU-dS-BC-PIIb | Start Date*: 2018-10-29 |
Sponsor Name:CUTISS AG | ||
Full Title: A Phase IIb, prospective, intra-patient randomised controlled, multicentre study to evaluate the safety and efficacy of an autologous bio-engineered dermo-epidermal skin substitute (EHSG-KF) for th... | ||
Medical condition: Children with partial deep dermal and full thickness burns | ||
Disease: | ||
Population Age: Newborns, Infants and toddlers, Children, Under 18 | Gender: Male, Female | |
Trial protocol: NL (Trial now transitioned) IT (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2017-004901-41 | Sponsor Protocol Number: PREFERCABG01 | Start Date*: 2018-04-19 |
Sponsor Name:Hospital District of Southwestern Finland | ||
Full Title: A Phase IV Double-blind, Randomised, Parallel Group Comparison of the Efficacy and Safety of Preoperative Intravenous Ferric Carboxymaltose and Placebo in the Treatment of Patients Undergoing Elect... | ||
Medical condition: Patients undergoing elective coronary artery bypass grafting surgery, the study investigates the prevention of postoperative infections and blood transfusions. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FI (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2013-005127-16 | Sponsor Protocol Number: IG1101 | Start Date*: 2014-06-16 |
Sponsor Name:Instituto Grifols, S.A. | ||
Full Title: A Prospective, Single-blind, Randomized, Phase III Study to Evaluate the Safety and Efficacy of Fibrin Sealant Grifols (FS Grifols) as an Adjunct to Hemostasis during Peripheral Vascular Surgery | ||
Medical condition: Treatment of haemorrhage resulting from a vascular surgical procedure | ||
Disease: | ||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: HU (Completed) | ||
Trial results: View results |
EudraCT Number: 2008-000072-25 | Sponsor Protocol Number: IG402 | Start Date*: 2008-08-04 |
Sponsor Name:Instituto Grifols S.A. | ||
Full Title: Estudio prospectivo, simple ciego, de Fase II/III para evaluar la Seguridad y Eficacia del Adhesivo de Fibrina Grifols (FS Grifols) como un Adyuvante a la Hemostasia durante Cirugía Vascular Perifé... | ||
Medical condition: Adyuvante a la hemostasia en cirugía vascular periférica. Adjunct to hemostasis during peripheral vascular surgery. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Completed) GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2004-004348-39 | Sponsor Protocol Number: 2004HS0191H | Start Date*: 2005-06-14 |
Sponsor Name:Royal Brompton & Harefield NHS Trust | ||
Full Title: Effect of Strict Control of Blood Sugar with Insulin Regimen on Prevention of Atrial Fibrillation after Coronary Artery Bypass Grafting. | ||
Medical condition: Atrial Fibrillation following Coronary Artery Bypass Grafting operation. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2012-000449-11 | Sponsor Protocol Number: EP250567 | Start Date*: 2012-03-01 | |||||||||||
Sponsor Name:Eero Pesonen | |||||||||||||
Full Title: Heparin dose (300 IU/kg vs. 600 IU/kg) in coroanry artery bypass grafting | |||||||||||||
Medical condition: Patients undergoing elective coronary artery bypass grafting | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-002790-35 | Sponsor Protocol Number: C12-48 | Start Date*: 2019-06-04 | |||||||||||
Sponsor Name:INSERM | |||||||||||||
Full Title: Phase I/II ex vivo gene therapy clinical trial for RDEB using autologous skin equivalent grafts genetically corrected with a COL7A1-encoding SIN retroviral vector | |||||||||||||
Medical condition: The trial aims to treat the recessive dystrophic epidermolysis bullosa (RDEB) by grafting one to three subjects with RDEB with autologous COL7A1-modified skin equivalents, using SIN-RV encoding COL... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-000369-12 | Sponsor Protocol Number: MOX-420-WIE-0030-I | Start Date*: 2006-05-24 |
Sponsor Name:Institute of Anaesthesiology, German Heart Centre | ||
Full Title: An open, randomized, single-center study assessing the serum time-concentration curves and the effect of prophylactic moxifloxacin (in comparison with cefuroxime) on the early inflammatory response... | ||
Medical condition: In this study prophylactic moxifloxacin 400 mg i.v. is compared with the above mentioned standard antibiotic prophylaxis cefuroxime regimen with special consideration to the postoperative inflammat... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2005-005960-95 | Sponsor Protocol Number: 2006UK-001 | Start Date*: 2006-04-26 |
Sponsor Name:Enturia, Inc. | ||
Full Title: Prospective, randomised clinical trial to compare the efficacy of 0.5% (w/v) chlorhexidine gluconate in 70% (v/v) isopropyl alcohol with 2% (w/v) chlorhexidine gluconate in 70% (v/v) isopropyl alco... | ||
Medical condition: This product is a skin disinfectant and therefore is not specific for a medicinal condition. It will be used where patients require skin disinfection prior to surgery and for care of the surgical ... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2006-005092-18 | Sponsor Protocol Number: CS I-020502/01 | Start Date*: 2007-01-08 | |||||||||||
Sponsor Name:KUROS BIOSURGERY AG | |||||||||||||
Full Title: A phase 2a, multi-centre, controlled study of the safety and efficacy of wound healing gel I-020502 in patients undergoing autologous meshed skin grafting. | |||||||||||||
Medical condition: Deep partial-thickness and full-thickness burns require grafting procedures to achieve wound healing and closure. Autologous grafting eliminates the risk of transmissible diseases but may be compli... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-005186-31 | Sponsor Protocol Number: 01062017 | Start Date*: 2018-06-06 | ||||||||||||||||
Sponsor Name:Department of Plastic Surgery, Breast and Burns Treatment | ||||||||||||||||||
Full Title: Fat Grafting with Ex-Vivo Expanded Adipose-Derived Stem Cells for Breast Reconstruction Following Mastectomy | ||||||||||||||||||
Medical condition: This study will include patients with genetic predisposition to development of breast cancer, who are offered prophylactic bilateral skin-sparring mastectomy. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Female | |||||||||||||||||
Trial protocol: DK (Prematurely Ended) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-005664-10 | Sponsor Protocol Number: BMP2/1 | Start Date*: 2015-09-30 |
Sponsor Name:UZ Leuven Orthopedic research | ||
Full Title: InductOs® (rhBMP-2; dibotermin alfa) vs. autologous bone grafting for the treatment of nonunion of the docking site in tibial bone transport | ||
Medical condition: fractured non-healing tibia | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-002142-50 | Sponsor Protocol Number: POPCABG03 | Start Date*: 2019-04-09 |
Sponsor Name:St. Antonius Hospital | ||
Full Title: A Randomized, Double-Blind, Placebo-Controlled Trial Investigating The Effect Of Ticagrelor On Saphenous Vein Graft Patency In Patients Undergoing Coronary Artery Bypass Grafting Surgery. | ||
Medical condition: Coronary artery bypass grafting surgery with the use of one or more saphenous vein grafts. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2008-004771-22 | Sponsor Protocol Number: Vs.12.11-07-2008 | Start Date*: 2008-09-03 | |||||||||||||||||||||
Sponsor Name:Rigshospitalet, Kardiologisk afd | |||||||||||||||||||||||
Full Title: Prospective randomised dubbleblind placebocontrolled trial of calcium antagonist to prevent calcineurin induced nephropathy in lung transplanted patients | |||||||||||||||||||||||
Medical condition: kidney damage in ciclosporin treated lung transplant patients. | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: DK (Completed) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-001725-25 | Sponsor Protocol Number: RSA-HIP220306 | Start Date*: 2007-08-09 | |||||||||||
Sponsor Name:GREATER GLASGOW HEALTH BOARD | |||||||||||||
Full Title: REVISION HP REPLACEMENT - ACETABULAR IMPACTION GRAFTING - A RADIOSTEREOMETRIC COMPARISON BETWEEN FRESH FROZEN ALLOGRAFT AND MARROW-DEPLETED BONE WITH CALCIUM PHOSPHATE PLUS OR MINUS BONE MORPHOGENI... | |||||||||||||
Medical condition: REVISION HIP REPLACEMENT | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-003707-30 | Sponsor Protocol Number: P140501 | Start Date*: 2014-10-23 | |||||||||||
Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | |||||||||||||
Full Title: | |||||||||||||
Medical condition: | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-004284-21 | Sponsor Protocol Number: 987 | Start Date*: 2007-07-06 | |||||||||||
Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI | |||||||||||||
Full Title: A prospective randomized study of antibiotic prophylaxis for renal transplantation: short term vs standard treatment | |||||||||||||
Medical condition: antibiotic prophylaxis for renal tranplantation | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-000541-38 | Sponsor Protocol Number: CRAD001A2403 | Start Date*: 2004-09-27 | |||||||||||
Sponsor Name:NOVARTIS FARMA | |||||||||||||
Full Title: A Six-month, Multicenter, Randomized, Open-label Study of the Safety, Tolerability and Efficacy of Two Neoral Doses in addition to Certican 61668; and Steroids in de novo Heart Transplant Recipients. | |||||||||||||
Medical condition: Prophylaxis of organ rejection in adult patients at low to moderate immunological risk receiving an allogeneic renal or cardiac transplant. It should be used in combination with ciclosporin for mic... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
